LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)

DRUG2 trials

Sponsors

LEO Pharma

Conditions

Psoriasis VulgarisScalp Psoriasis

Phase 2

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

CompletedNCT01120223

LEO PharmaScalp Psoriasis

Start: 2010-05-31End: 2012-10-31Updated: 2025-03-11

Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

CompletedNCT01229098

LEO PharmaPsoriasis Vulgaris

Start: 2010-10-31End: 2011-10-31Updated: 2025-02-24